Targeting the oncogenic Met receptor by antibodies and gene therapy.
about
Mesenchymal stem cell-based NK4 gene therapy in nude mice bearing gastric cancer xenografts.YKL-40/c-Met expression in rectal cancer biopsies predicts tumor regression following neoadjuvant chemoradiotherapy: a multi-institutional studyMET inhibition overcomes radiation resistance of glioblastoma stem-like cells.C-met inhibition blocks bone metastasis development induced by renal cancer stem cells.MET expression and copy number status in clear-cell renal cell carcinoma: prognostic value and potential predictive marker.Progress of antibody-based inhibitors of the HGF-cMET axis in cancer therapy.Molecular targets of luteolin in cancerα-Ketobenzothiazole Serine Protease Inhibitors of Aberrant HGF/c-MET and MSP/RON Kinase Pathway Signaling in Cancer.The c-Met receptor: Implication for targeted therapies in colorectal cancer.MET in human cancer: germline and somatic mutations.Inhibition of pro-HGF activation by SRI31215, a novel approach to block oncogenic HGF/MET signaling.Probing conformational and functional states of human hepatocyte growth factor by a panel of monoclonal antibodiesTumor Inhibitory Effect of IRCR201, a Novel Cross-Reactive c-Met Antibody Targeting the PSI Domain.Characterizing the Hot Spots Involved in RON-MSPβ Complex Formation Using In Silico Alanine Scanning Mutagenesis and Molecular Dynamics Simulation.Dual Constant Domain-Fab: A novel strategy to improve half-life and potency of a Met therapeutic antibody.MiR-16 regulates the pro-tumorigenic potential of lung fibroblasts through the inhibition of HGF production in an FGFR-1- and MEK1-dependent manner.Monoclonal Antibodies against the MET/HGF Receptor and Its Ligand: Multitask Tools with Applications from Basic Research to Therapy.
P2860
Q34710895-29D629CE-5CC4-4654-870D-AA7E1D5E61E3Q35433475-6C75A75A-3CC0-4AE0-8CE4-49284A69F471Q37458626-73A7AF65-C1D7-4D11-953A-C8C2A02BF9E1Q37564471-8AB014D3-7AB9-4F0A-B03A-7099D22760D4Q37702041-E321D262-629D-479C-B3C1-DF7848761AF5Q37739477-3FCE7ECA-4E26-4D61-B24B-BD242EB57335Q38365120-E142B4F5-FFED-4547-AB46-7AC0309EAA9FQ38793227-9163FFD0-07FB-46D9-A1CD-86F78E70805AQ39274990-C689E5C8-5529-4934-99B9-DC4215F8DEB8Q39365962-7557735B-9AE0-4172-956F-756685549990Q39816968-46095C71-1D69-4FB5-8025-A9575ED797D3Q41051656-07D50D4F-708B-4A74-9857-297D3AD61460Q41660598-7EF9208D-4F56-42E1-B164-F249409C00F6Q42276494-D05E3F1A-03D8-4B19-AD9E-9F7DA16A21D1Q42282846-3EF4B8E6-2BB5-43CF-8BD9-DAFAF71BBB20Q52646457-F9FFFDCD-B56D-401D-A64B-E247F4CBB268Q53789447-591C59FE-B683-4741-AF18-8FCA86F7CB59
P2860
Targeting the oncogenic Met receptor by antibodies and gene therapy.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Targeting the oncogenic Met receptor by antibodies and gene therapy.
@en
type
label
Targeting the oncogenic Met receptor by antibodies and gene therapy.
@en
prefLabel
Targeting the oncogenic Met receptor by antibodies and gene therapy.
@en
P2860
P356
P1433
P1476
Targeting the oncogenic Met receptor by antibodies and gene therapy.
@en
P2093
P2860
P2888
P304
P356
10.1038/ONC.2014.142
P407
P577
2014-06-02T00:00:00Z
P6179
1016339526